LONDON - Drugs that combat obesity could for the first time be included on the World Health Organisation's "essential medicines list", used to guide government purchasing decisions in low- and middle-income countries, the UN agency told Reuters.
A panel of advisers to the WHO will review new requests for drugs to be included next month, with an updated essential medicines list due in September.
The request to consider obesity drugs was submitted by three doctors and a researcher in the US.
It covers the active ingredient liraglutide in Novo Nordisk's obesity drug Saxenda, which will come off patent soon, allowing for cheaper generic versions.
The panel could reject the request or wait for more evidence.
A decision by the WHO to include Saxenda and eventual generics on the list would mark a new approach to global obesity by the health agency.
It could also pave the way for a newer, more powerful treatment from Novo Nordisk called Wegovy to be recommended for low- and middle-income countries in future.
However, some public health experts warn against introducing such medicines too broadly as a solution to a complex condition that is still not completely understood.
"Obesity is an increasingly important health problem in many countries," said a WHO spokesperson. "Medicines for the treatment of obesity are only one aspect of management, of course, and prevention is also crucial."
The WHO said the expert panel would consider the evidence for liraglutide over the coming months.
They may also seek a broader evaluation of other types of weight-loss treatments in the future.
Over 650 million adults worldwide are obese, more than triple the rate in 1975, and roughly another 1.3 billion are overweight, according to the WHO.
The majority – 70 per cent – live in low- and middle-income countries.
Including obesity drugs among the WHO's essential medicines could have great significance for that population.
Experts say that adding HIV drugs to the list in 2002 helped to make them much more widely available to AIDS patients in poorer countries.
“At present, there are no medications included in the (list) that specifically target weight loss for the ongoing global burden of obesity,” wrote US researcher Dr Sanjana Garimella from Yale New Haven Health, Dr Sandeep Kishore from the University of California, San Francisco, and colleagues to the WHO in requesting the addition.
They did not respond to Reuters requests for comment.
They argue that while the list includes mineral supplements for nutritional deficiencies, the lack of weight-loss treatments represents a "discrepancy" in global health equity, given the increasing number of deaths in poorer nations hastened by weight-related illness, including heart disease and diabetes.
Saxenda, a once-daily injection, has been shown to help people reduce five to 10 per cent of their body weight, at US$450 (S$600) per month in the US and US$150 per month in Europe.
People using Wegovy, a weekly injection that costs more than US$1,300 a month in the US, have lost up to 15 per cent of their weight.
At the moment, Wegovy is in short supply and Novo is prioritising its launch and distribution in the US and other wealthy markets.
The Danish drugmaker in a statement said it was not involved in the application to consider liraglutide for inclusion on the WHO list, adding, "we welcome the WHO review and look forward to the readout and decision".
Both drugs belong to a class of medicines called GLP-1 receptor agonists, which have been used for years to treat diabetes.
They affect hunger signals to the brain and slow the rate at which a person’s stomach empties, making them feel fuller longer.
Eli Lilly and Co has a similar diabetes drug nearing approval for weight loss.
For both Saxenda and Wegovy, there is a lack of long-term safety and effectiveness data for obesity.
Studies suggest people will likely have to take the drugs for the rest of their lives to keep the weight off.
High-income countries are taking varying approaches for how to use these medicines, including contemplating whether they can be prescribed by government-sponsored health systems or covered by insurance, as they are for diabetes.
In some countries, their use is being reserved only for the most at-risk groups.
Professor Zulfiqar Bhutta, an obesity expert at the University of Toronto, said the phenomenon of obesity in low- and middle-income countries must be better understood to help determine the best course of action
"Preventive strategies and sustained efforts at education, gender-focused interventions, must take precedence over the use of obesity drugs, which require a lot more research for safety and effectiveness," he said.